Epidermal growth factor receptor (EGFR) signaling regulates global metabolic pathways in EGFR-mutated lung adenocarcinoma

Journal of Biological Chemistry

Volumn 289, Issue 30, 2014, Pages 20813-20823

  Makinoshima, Hideki ^a   Takita, Masahiro ^a,b   Matsumoto, Shingo ^a,c   Yagishita, Atsushi ^a   Owada, Satoshi ^d   Esumi, Hiroyasu ^d   Tsuchihara, Katsuya ^a,b  

^a NATIONAL CANCER CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^d TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTATE CARBAMOYLTRANSFERASE; CAD TRIFUNCTIONAL ENZYME; CARBAMOYL PHOSPHATE SYNTHASE (GLUTAMINE HYDROLYSING); DIHYDROOROTASE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GLUCOSE; GLUCOSE TRANSPORTER 3; LACTIC ACID; SLC2A3 PROTEIN, HUMAN; TUMOR PROTEIN;

ADENOCARCINOMA; GENETICS; GLYCOLYSIS; HUMAN; LUNG TUMOR; METABOLISM; PATHOLOGY; PENTOSE PHOSPHATE CYCLE; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADENOCARCINOMA; ASPARTATE CARBAMOYLTRANSFERASE; CARBAMOYL-PHOSPHATE SYNTHASE (GLUTAMINE-HYDROLYZING); CELL LINE, TUMOR; DIHYDROOROTASE; EPIDERMAL GROWTH FACTOR; GLUCOSE; GLUCOSE TRANSPORTER TYPE 3; GLYCOLYSIS; HUMANS; LACTIC ACID; LUNG NEOPLASMS; NEOPLASM PROTEINS; PENTOSE PHOSPHATE PATHWAY; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84905371455     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M114.575464     Document Type: Article

References (45)

1. da Cunha Santos, G., Shepherd, F. A., and Tsao, M. S. (2011) EGFR mutations and lung cancer. Annu. Rev. Pathol. 6, 49-69
2. Irmer, D., Funk, J. O., and Blaukat, A. (2007) EGFR kinase domain mutations - functional impact and relevance for lung cancer therapy. Oncogene 26, 5693-5701
3. Levitzki, A. (2013) Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical performance. Annu. Rev. Pharmacol. Toxicol. 53, 161-185
4. Linardou, H., Dahabreh, I. J., Bafaloukos, D., Kosmidis, P., and Murray, S. (2009) Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC. Nat. Rev. Clin. Oncol. 6, 352-366
5. Suzuki, A., Mimaki, S., Yamane, Y., Kawase, A., Matsushima, K., Suzuki, M., Goto, K., Sugano, S., Esumi, H., Suzuki, Y., and Tsuchihara, K. (2013) Identification and characterization of cancer mutations in Japanese lung adenocarcinoma without sequencing of normal tissue counterparts. PLoS One 8, e73484
6. Imielinski, M., Berger, A. H., Hammerman, P. S., Hernandez, B., Pugh, T. J., Hodis, E., Cho, J., Suh, J., Capelletti, M., Sivachenko, A., Sougnez, C., Auclair, D., Lawrence, M. S., Stojanov, P., Cibulskis, K., Choi, K., de Waal, L., Sharifnia, T., Brooks, A., Greulich, H., Banerji, S., Zander, T., Seidel, D., Leenders, F., Ansén, S., Ludwig, C., Engel-Riedel, W., Stoelben, E., Wolf, J., Goparju, C., Thompson, K., Winckler, W., Kwiatkowski, D., Johnson, B. E., Jänne, P. A., Miller, V. A., Pao, W., Travis, W. D., Pass, H. I., Gabriel, S. B., Lander, E. S., Thomas, R. K., Garraway, L. A., Getz, G., and Meyerson, M. (2012) Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing. Cell 150, 1107-1120
7. Mellinghoff, I. (2007) Why do cancer cells become "addicted" to oncogenic epidermal growth factor receptor? Plos Med. 4, 1620-1622
8. Pao, W., and Chmielecki, J. (2010) Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nature Reviews Cancer 10, 760-774
9. Lemmon, M. A., and Schlessinger, J. (2010) Cell signaling by receptor tyrosine kinases. Cell 141, 1117-1134
10. Cairns, R. A., Harris, I. S., and Mak, T. W. (2011) Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95
11. Levine, A. J., and Puzio-Kuter, A. M. (2010) The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 330, 1340-1344
12. Cheong, H., Lu, C., Lindsten, T., and Thompson, C. B. (2012) Therapeutic targets in cancer cell metabolism and autophagy. Nat. Biotechnol. 30, 671-678
13. Ying, H., Kimmelman, A. C., Lyssiotis, C. A., Hua, S., Chu, G. C., Fletcher-Sananikone, E., Locasale, J. W., Son, J., Zhang, H., Coloff, J. L., Yan, H., Wang, W., Chen, S., Viale, A., Zheng, H., Paik, J. H., Lim, C., Guimaraes, A. R., Martin, E. S., Chang, J., Hezel, A. F., Perry, S. R., Hu, J., Gan, B., Xiao, Y., Asara, J. M., Weissleder, R., Wang, Y. A., Chin, L., Cantley, L. C., and DePinho, R. A. (2012) Oncogenic Kras maintains pancreatic tumors through regulation of anabolic glucose metabolism. Cell 149, 656-670
14. Lunt, S. Y., and Van der Heiden, M. G. (2011) Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol. 27, 441-464
15. Soga, T. (2013) Cancer metabolism: key players in metabolic reprogramming. Cancer Sci. 104, 275-281
16. Van der Heiden, M. G., Cantley, L. C., and Thompson, C. B. (2009) Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 324, 1029-1033
17. Hitosugi, T., Kang, S., Van der Heiden, M. G., Chung, T. W., Elf, S., Lythgoe, K., Dong, S., Lonial, S., Wang, X., Chen, G. Z., Xie, J., Gu, T. L., Polakiewicz, R. D., Roesel, J. L., Boggon, T. J., Khuri, F. R., Gilliland, D. G., Cantley, L. C., Kaufman, J., and Chen, J. (2009) Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci. Signal 2, ra73
18. Hitosugi, T., and Chen, J. (2013) Post-translational modifications and the Warburg effect. Oncogene doi:10.1038/onc.2013.406
19. Miller, D. M., Thomas, S. D., Islam, A., Muench, D., and Sedoris, K. (2012) c-Myc and cancer metabolism. Clin. Cancer Res. 18, 5546-5553
20. Yang, W., and Lu, Z. (2013) Nuclear PKM2 regulates the Warburg effect. Cell Cycle 12, 3154-3158
21. Wong, N., Ojo, D., Yan, J., and Tang, D. (2014) PKM2 contributes to cancer metabolism. Cancer Lett. doi: 10.1016/j.canlet. 2014.01.031
22. Babic, I., Anderson, E. S., Tanaka, K., Guo, D., Masui, K., Li, B., Zhu, S., Gu, Y., Villa, G. R., Akhavan, D., Nathanson, D., Gini, B., Mareninov, S., Li, R., Camacho, C. E., Kurdistani, S. K., Eskin, A., Nelson, S. F., Yong, W. H., Cavenee, W. K., Cloughesy, T. F., Christofk, H. R., Black, D. L., and Mischel, P. S. (2013) EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 17, 1000-1008
23. Soga, T., and Heiger, D. N. (2000) Amino acid analysis by capillary electrophoresis electrospray ionization mass spectrometry. Anal. Chem. 72, 1236-1241
24. Soga, T., Ueno, Y., Naraoka, H., Ohashi, Y., Tomita, M., and Nishioka, T. (2002) Simultaneous determination of anionic intermediates for Bacillus subtilis metabolic pathways by capillary electrophoresis electrospray ionization mass spectrometry. Anal. Chem. 74, 2233-2239
25. Soga, T., Ohashi, Y., Ueno, Y., Naraoka, H., Tomita, M., and Nishioka, T. (2003) Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J. Proteome Res. 2, 488-494
26. Su, H., Bodenstein, C., Dumont, R. A., Seimbille, Y., Dubinett, S., Phelps, M. E., Herschman, H., Czernin, J., and Weber, W. (2006) Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors. Clin. Cancer Res. 12, 5659-5667
27. Okamoto, K., Okamoto, I., Okamoto, W., Tanaka, K., Takezawa, K., Kuwata, K., Yamaguchi, H., Nishio, K., and Nakagawa, K. (2010) Role of survivin in EGFR inhibitor-induced apoptosis in non-small cell lung cancers positive for EGFR mutations. Cancer Res. 70, 10402-10410
28. Donev, I. S., Wang, W., Yamada, T., Li, Q., Takeuchi, S., Matsumoto, K., Yamori, T., Nishioka, Y., Sone, S., and Yano, S. (2011) Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFRTKIs in EGFR mutant lung cancer. Clin. Cancer Res. 17, 2260-2269
29. Zhou, W., Ercan, D., Chen, L., Yun, C. H., Li, D., Capelletti, M., Cortot, A. B., Chirieac, L., Iacob, R. E., Padera, R., Engen, J. R., Wong, K. K., Eck, M. J., Gray, N. S., and Jänne, P. A. (2009) Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature 462, 1070-1074
30. Sudo, M., Chin, T. M., Mori, S., Doan, N. B., Said, J. W., Akashi, M., and Koeffler, H. P. (2013) Inhibiting proliferation of gefitinib-resistant, nonsmall cell lung cancer. Cancer Chemother. Pharmacol. 71, 1325-1334
31. Sonveaux, P., Végran, F., Schroeder, T., Wergin, M. C., Verrax, J., Rabbani, Z. N., De Saedeleer, C. J., Kennedy, K. M., Diepart, C., Jordan, B. F., Kelley, M. J., Gallez, B., Wahl, M. L., Feron, O., and Dewhirst, M. W. (2008) Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J. Clin. Invest. 118, 3930-3942
32. Morrish, F., Neretti, N., Sedivy, J. M., and Hockenbery, D. M. (2008) The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. Cell Cycle 7, 1054-1066
33. Osthus, R. C., Shim, H., Kim, S., Li, Q., Reddy, R., Mukherjee, M., Xu, Y., Wonsey, D., Lee, L. A., and Dang, C. V. (2000) Deregulation of glucose transporter 1 and glycolytic gene expression by c-Myc. J. Biol. Chem. 275, 21797-21800
34. David, C. J., Chen, M., Assanah, M., Canoll, P., and Manley, J. L. (2010) HnRNP proteins controlled by c-Myc deregulate pyruvate kinase mRNA splicing in cancer. Nature 463, 364-368
35. Ben-Sahra, I., Howell, J. J., Asara, J. M., and Manning, B. D. (2013) Stimulation of de novo pyrimidine synthesis by growth signaling throughmTOR and S6K1. Science 339, 1323-1328
36. Weihua, Z., Tsan, R., Huang, W. C., Wu, Q., Chiu, C. H., Fidler, I. J., and Hung, M. C. (2008) Survival of cancer cells is maintained by EGFR independent of its kinase activity. Cancer Cell 13, 385-393
37. Watson, R. T., and Pessin, J. E. (2006) Bridging the GAP between insulin signaling and GLUT4 translocation. Trends Biochem. Sci. 31, 215-222
38. Bogan, J. S. (2012) Regulation of glucose transporter translocation in health and diabetes. Annu. Rev. Biochem. 81, 507-532
39. Wu, N., Zheng, B., Shaywitz, A., Dagon, Y., Tower, C., Bellinger, G., Shen, C. H., Wen, J., Asara, J., McGraw, T. E., Kahn, B. B., and Cantley, L. C. (2013) AMPK-dependent degradation of TXNIP upon energy stress leads to enhanced glucose uptake via GLUT1. Mol. Cell 49, 1167-1175
40. Zhang, C., Liu, J., Liang, Y., Wu, R., Zhao, Y., Hong, X., Lin, M., Yu, H., Liu, L., Levine, A. J., Hu, W., and Feng, Z. (2013) Tumour-associated mutant p53 drives the Warburg effect. Nat. Commun. 4, 2935
41. Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y. M., Park, K., Kim, S. W., Zhou, C., Su, W. C., Wang, M., Sun, Y., Heo, D. S., Crino, L., Tan, E. H., Chao, T. Y., Shahidi, M., Cong, X. J., Lorence, R. M., and Yang, J. C. (2012) Afatinib versus placebo for patients with advanced, metastatic non-smallcell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 13, 528-538
42. Kim, S. M., Yun, M. R., Hong, Y. K., Solca, F., Kim, J. H., Kim, H. J., and Cho, B. C. (2013) Glycolysis inhibition sensitizes non-small cell lung cancer with T790M mutation to irreversible EGFR inhibitors via translational suppression of Mcl-1 by AMPK activation. Mol. Cancer Ther. 12, 2145-2156
43. Takahashi, R., Hirata, H., Tachibana, I., Shimosegawa, E., Inoue, A., Nagatomo, I., Takeda, Y., Kida, H., Goya, S., Kijima, T., Yoshida, M., Kumagai, T., Kumanogoh, A., Okumura, M., Hatazawa, J., and Kawase, I. (2012) Early [18F]fluorodeoxyglucose positron emission tomography at two days of gefitinib treatment predicts clinical outcome in patients with adenocarcinoma of the lung. Clin. Cancer Res. 18, 220-228
44. Spratlin, J. L., Serkova, N. J., and Eckhardt, S. G. (2009) Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 15, 431-440
45. Kami, K., Fujimori, T., Sato, H., Sato, M., Yamamoto, H., Ohashi, Y., Sugiyama, N., Ishihama, Y., Onozuka, H., Ochiai, A., Esumi, H., Soga, T., and Tomita, M. (2013) Metabolomic profiling of lung and prostate tumor tissues by capillary electrophoresis time-of-flight mass spectrometry. Metabolomics 9, 444-453